PixarBio Corporation Continues Infrastructure Expansion for Commercialization

CAMBRIDGE, Mass.--()--PixarBio Corporation today announced that it is adding 5,000 Sq. feet of office space in Fort Lee, NJ. The space will support 10 current staff and up to 40 future staff and will it be home for PixarBio-New York for the next 7 years.

“FDA approval for NeuroRelease’s 14 day post-op pain treatment is expected in 2018 and it will truly change the practice of medicine. PixarBio is now front and center in the race to develop the first FDA approved long acting Morphine strength, Non-addictive pain treatment that can defeat “Rebound Pain”

There are only three companies at the US FDA with non-addictive, post-operative pain treatments and PixarBio’s NeuroRelease is the only treatment that can extend past 5 days to prevent “Rebound Pain”, which contributes to the cycle of opiate addiction. Recent FDA Black Labels for ALL opiates and the CDC’s April 2016 actions around the limitations of opiate usage for chronic pain patients, have triggered significant demand and interest for NeuroRelease Pain.

“FDA approval for NeuroRelease’s 14 day post-op pain treatment is expected in 2018 and it will truly change the practice of medicine. PixarBio is now front and center in the race to develop the first FDA approved long acting Morphine strength, Non-addictive pain treatment that can defeat “Rebound Pain” and we will not let PixarBio stakeholders down,” said CEO Frank Reynolds.

The demand for post-op pain treatment is over 70,000,000+ surgeries annually in the USA. It’s a daunting task but PixarBio’s experienced team of industry veterans won’t fail. The New York- New Jersey Region is home to over 500,000 Pharmaceutical Industry veterans so it represents a great place to recruit talent whether they’re from the New York City region, the Parsippany NJ-Bethlehem PA region, or the Southern NJ region, Fort Lee is accessible to all.

Governor Christie of New Jersey Combating Opiates

“New Jersey and New York share a close relationship in which our residents regularly travel between the states for business and pleasure. Today we’re coming together for another purpose – to fight the devastating scourge of opiate drug addiction” New Jersey Gov. Chris Christie

“We now have Labs and offices located in Fort Lee NJ, Salem NH, Cambridge MA, and Medford MA. The Governors of NJ, MA, and NH have all been strong proponents of battling the Opioid/Opiate crisis and we look forward to providing physicians and legislators with a Morphine strength, non-addictive option for pain treatment,” said PixarBio CEO Frank Reynolds.

About PixarBio Corporation
Cofounded by Frank Reynolds, MIT’s Dr. Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio researches and develops targeted delivery systems to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For more information visit www.pixarbio.com.

Contacts

PixarBio Corporation
Glenn Reiser
617-386-6795
Vice President, External Affairs
investorrelations@pixarbio.com

Recent Stories

RSS feed for PixarBio Corporation